LIVERPOOL, England (Reuters) - A British court will hear an appeal on Wednesday in the case of a gravely ill, 23-month-old boy whose case has attracted international attention, including from Pope Francis.
ZURICH (Reuters) - Novartis's foray into digital technology intensified on Wednesday as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.
(Reuters Health) - Pregnant women who drink lots of coffee and other caffeinated beverages may be more likely to have kids who are overweight than mothers who limit caffeine during pregnancy, a Norwegian study suggests.
LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc, Eli Lilly and Co and other makers of new migraine medicines to try and fix it.
GENEVA (Reuters) - Malaria is spreading rapidly in crisis-hit Venezuela, with more than an estimated 406,000 cases in 2017, up roughly 69 percent from a year before, the largest increase worldwide, the World Health Organization (WHO) said on Tuesday.
LONDON (Reuters) - The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study.
LONDON (Reuters) - A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention program.
LONDON (Reuters) - A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping patients live longer.
LOS ANGELES (Reuters) - The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it.
(Reuters) - An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.
(Reuters Health) - Electromagnetic fields produced by motors in electric cars don’t appear strong enough to interfere with implanted heart devices like pacemakers and defibrillators, a small German study suggests.
(Reuters) - A rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp should not be approved at a higher dose, a U.S. Food and Drug Administration advisory committee voted on Monday, while backing the approval of a lower dose.
(Reuters) - A U.S. FDA advisory committee voted 10-to-5 on Monday against approving a higher dose of a rheumatoid arthritis drug developed by Eli Lilly & Co and Incyte Corp, but recommended that it be approved in a lower dose.